| |
Home »
News » 02/06
» Allergan Botox could be used to fight cancer
Allergan Botox could be used to fight cancer
Date published: 16/02/2006
Botox
could be used alongside chemotherapy and radiation to fight cancer, new
research has suggested. The cosmetic treatment produced by
Allergan, which is normally used to
smooth wrinkles, was found to destroy resistant cancer cells in tests on mice.
Professor Bernard Gallez from Louvain University in Brussels injected
botulinum neurotoxin type A, otherwise known as Botox, into two types of
cancerous tumours in mice. After injecting the tumours they were then examined
for three days. The team found it could slow the growth of the tumour and
hindered the action of the neurotransmitters which the tumours rely on to grow.
Professor Gallez says the treatment could be used as a "pre-treatment"
to other conventional cancer treatments. He said: "Hypoxia is a source of
resistance to radiotherapy, and is a determining factor in the poor prognosis
of tumours to cytotoxic treatments. "Botulinum toxin could lead to inhibition
of contractions of tumour vessels, improve tumour perfusion and oxygenation,
and enhance the response of tumours to radio- and chemotherapy."
Since
Botox is used in cosmetic procedures with few adverse reactions, the team says
it may soon be possible to carry out human trials. The dosages used in the
mouse study were also within the range used in humans in current Botox
procedures. They also said it had the capacity to destroy tumour cells without
harming healthy tissue. Professor Gallez says this could give Botox the edge
over other treatments such as chemotherapy which can sometimes damage healthy
cells.
© Adfero Ltd
Disclaimer
AllAboutMedicalSales excludes any warranty, express or implied, as to
the quality, accuracy, timeliness, completeness or fitness for a particular
purpose of this briefing. AllAboutMedicalSales will not be liable for any
claims, penalties, losses, damages, costs, or expenses arising from the use of
or inability to use this briefing or from any unauthorised access to or
alteration of the Briefing. AllAboutMedicalSales makes no warranty that the
contents of this briefing are compatible with all computer systems and
browsers.
|